<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> (5-FU) is a key chemotherapeutic agent in the treatment of many gastrointestinal tract <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Despite its proven therapeutic efficacy, 5-FU also possesses several undesired cardiac toxicities, including <z:e sem="disease" ids="C0010073" disease_type="Disease or Syndrome" abbrv="">coronary vasospasm</z:e>, coronary <z:mp ids='MP_0005048'>thrombosis</z:mp>, <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo>, and <z:hpo ids='HP_0001645'>sudden cardiac death</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>This review addresses the incidence, mechanisms of action, clinical presentation, risk stratification, and management of 5-FU associated cardiotoxicity; it also highlights the importance of careful pre-administration cardiac risk stratification and close monitoring during and after drug administration </plain></SENT>
<SENT sid="3" pm="."><plain>(Cardiol J 2012; 19, 5: 453-458) </plain></SENT>
</text></document>